MYC and neoplasm: Moreover, some instances of preclinical data have reported that LMS patient-derived xenografts (PDXs) (Ley16) associated with the gain of the functions PTEN, c-MYC, and/or HRD signatures, when treated by a PARP-inhibitor (Olaparib), resulted in a slower rate of tumor proliferation compared to the control [26].